Vaxxinity Inc

NASDAQ:VAXXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer’s disease (AD) and UB-312, which targets the pathological process of Parkinson’s disease (PD) and other so-called synucleinopathies.

Contact Information

Headquarters

1717 Main Street, Suite 3388DALLAS, TX, United States 75201

Phone

254-244-5739

Fax

302-636-5454

Executives

Executive Chairman

Louis Reese

President, Chief Executive Officer, Co-Founder, Director

Mei Mei Hu

Senior Vice President - Finance and Accounting

Jason Pesile

Chief Legal & Administrative Officer

Sumita Ray

Chief Scientific Officer

Farshad Guirakhoo